POST Online Media Lite Edition


FTC: Akorn Enterprises' acquisition of Hi-Tech Pharmacal anticompetitive

Staff writer |
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Akorn E.

Article continues below

FTC says that it would lead to higher prices for consumers in several current and future generic drug markets.

According to the FTC's complaint, originally announced in April 2014, the acquisition as proposed would reduce competition in the markets for four generic medications, including eye drops and topical anesthetics, and would reduce future competition in the market for a generic ointment prescribed to treat bacterial eye infections.

The final order settling the FTC's charges requires the parties to sell either Akorn's or Hi-Tech's rights and assets to each of the five drug products to Watson Laboratories, Inc., and required Akorn to assign Watson its contract for making a currently available branded and generic topical anesthetic cream within 10 days after the deal is completed.

What to read next

Akorn to buy VPI Holdings for $440m
Fresenius Kabi to acquire Akorn for $34 per share
Air Liquide’s acquisition of Airgas cleared by FTC